Search

Displaying results 5631 - 5640 of 7540 in total
  1. Drug

    Lonazolac

    go.drugbank.com/drugs/DB13432
    Experimental

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  2. Drug

    Debamestrocel

    go.drugbank.com/drugs/DB17934
    Investigational

    Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47266]

  3. Drug

    Antithrombin Alfa

    go.drugbank.com/drugs/DB11166
    Approved

    Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations.

  4. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    It is being developed by Avicena Group, Inc.

  5. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  6. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]

  7. Drug

    Bacteroides thetaiotaomicron

    go.drugbank.com/drugs/DB17879
    Investigational

    Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.[A259892]

  8. Drug

    99mTc-glucarate

    go.drugbank.com/drugs/DB05810
    Investigational

    99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.

  9. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

  10. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.